Menu
After spending decades in the shadows, psychedelics and empathogens have slowly reemerged as an effective treatment option for a wide variety of behavioral health issues including depression, anxiety, PTSD, chronic inflammation and addiction. With the cannabis legalization movement creeping towards maturity, American society has moved towards a more open-minded approach when it comes to this family of drugs that remain legally classified as a Schedule I substance under the Controlled Substances Act as the potential to provide relief to millions of afflicted people is an opportunity to large to ignore.
With a regulatory pathway already established, the next barrier is funding, but in order to drive greater investment, all interested parties must first understand the opportunity; from size and scope to models and applications.